Atypical antipsychotic that displays combined serotonin and dopamine receptor antagonism. Displays high affinity at 5-HT2A
receptors with a 5-HT2A
affinity ratio greater than any other clinically available atypical antipsychotics (pKi
values are 9.38, 8.88, 8.69, 8.47, 8.32, 8.14, 7.98, 7.49, 7.33 and 6.28 for 5-HT2A
Soluble to 10 mM in DMSO
Store at RT
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger et al.
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.
Schmidt et al.
Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats.
Fell et al.
Behav.Brain Res., 2005;160:338
The citations listed below are publications that use Tocris products. Selected citations for Ziprasidone hydrochloride include:
Showing Results 1 - 3 of 3